These include agents to reduce or prevent the production of causative proteins such as chemotherapeutic agents against plasma cell dyscrasia for AL amyloidosis, short interfering RNA and antisense oligonucleotides to knockdown TTR for ATTR amyloidosis, and monoclonal antibodies against proinflammatory cytokines for AA amyloidosis [7,10,59,60]. This evidence concerns the gene TTR and AL amyloidosis.